Amatayakul K, Sivassomboon B, Singkamani R
Contraception. 1980 Mar;21(3):283-97. doi: 10.1016/0010-7824(80)90007-4.
Proteins (total, albumin, globulin and their subfractions), carbohydrate (intravenous glucose tolerance test), lipids (serum cholesterol, triglycerides and phospholipids), and liver function tests (alkaline phosphatase, lactic dehydrogenase and aspartate aminotransferase activities in the serum, bromsulphathalein retention test and serum bilirubin) were studied in 12 non-lactating healthy Thai subjects before, and subsequently at 3 weeks and 3, 6, 9 and 12 months after the initiation of treatment with injectable medroxyprogesterone acetate (150 mg I.M. every 90 days). Serum protein and lipid levels, and the results of liver function and I.V. glucose tolerance tests, remained unchanged in all subjects throughout the one-year study period. However, a significant and persistent increased insulin level was noted in all subjects, after initiation of the hormone treatment, during the first thirty minutes of intravenous glucose load. It is concluded that injectable medroxyprogesterone acetate used as a contraceptive agent does not interfere with glucose tolerance, lipid and protein metabolism, and that the liver function remains normal during its administration.
对12名非哺乳期健康泰国受试者在注射醋酸甲羟孕酮（每90天肌肉注射150毫克）治疗前、治疗后3周以及3、6、9和12个月，研究了蛋白质（总量、白蛋白、球蛋白及其亚组分）、碳水化合物（静脉葡萄糖耐量试验）、脂质（血清胆固醇、甘油三酯和磷脂）以及肝功能（血清碱性磷酸酶、乳酸脱氢酶和天冬氨酸氨基转移酶活性、酚四溴酞钠潴留试验和血清胆红素）。在整个一年的研究期间，所有受试者的血清蛋白质和脂质水平以及肝功能和静脉葡萄糖耐量试验结果均保持不变。然而，在激素治疗开始后，所有受试者在静脉注射葡萄糖负荷的前30分钟内，胰岛素水平均出现显著且持续的升高。结论是，用作避孕药的注射用醋酸甲羟孕酮不干扰葡萄糖耐量以及脂质和蛋白质代谢，且在给药期间肝功能保持正常。
